Commercialization

NOVAJoint Project Commercial Partners

Commercialization

graphic depicting cellular structure and dna with text Leading Through Innovation

Aligned with the key goals of the NITRO program, the NOVAJoint team is aiming for the successful translation of NOVAJoint from the research lab to an FDA-approved implant

accessible to OA patients. To make this a reality, the NOVAJoint team is working closely with Columbia Technology Ventures (CTV) and LIS BioConsulting throughout the entire project.

 

If you would like to get involved as a commercial partner or investor, please contact us.

novajoint@cumc.columbia.edu